Resource Logo
AIDS Treatment Data Network

(ATDN) Interleukin-2 for HIV


Treatment Review #17 - March 1995

A trial studying IL-2 by subcutaneous injection for the treatment of HIV infection is enrolling in New York and other cities. Because of the side effects of IV infusion, some doctors are giving the drug by subcutaneous injection. This trial will study the combination of IL-2 and AZT. Participants will be divided into two groups. Everyone will take AZT. The first group will also be given shots of IL-2. After 24 weeks, the second group will be given shots of IL-2 and the first group will take only AZT. To participate in this study you must be HIV+, 18 years or older, and have a T4 cell count between 300 and 700. You must have taken and tolerated AZT for 6 months or longer at 500 mg./day. You cannot have any opportunistic illnesses or be pregnant or nursing. Call The Network for more information.


Copyright © 1995 -AIDS Treatment Data Network, Publisher. All rights reserved to AIDS Treatment Data Network. Reproduction of this article (other than one copy for personal reference) must be cleared through the AIDS Treatment Data Network. Email AIDS Treatment Data Network

Information in this article was accurate in March 1, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.